Tianjin Hemay Pharmaceutical Co., Ltd
Quick facts
Phase 3 pipeline
- Hemay022+AI · Oncology
Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity. - Lapatinib+Capecitabine · Oncology
Lapatinib inhibits HER2 and EGFR tyrosine kinases while capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, together targeting HER2-positive breast cancer through dual mechanisms.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: